KR102711884B1 - 항-par2 항체 및 그의 용도 - Google Patents

항-par2 항체 및 그의 용도 Download PDF

Info

Publication number
KR102711884B1
KR102711884B1 KR1020197030092A KR20197030092A KR102711884B1 KR 102711884 B1 KR102711884 B1 KR 102711884B1 KR 1020197030092 A KR1020197030092 A KR 1020197030092A KR 20197030092 A KR20197030092 A KR 20197030092A KR 102711884 B1 KR102711884 B1 KR 102711884B1
Authority
KR
South Korea
Prior art keywords
delete delete
antibody
ser
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030092A
Other languages
English (en)
Korean (ko)
Other versions
KR20190129925A (ko
Inventor
클레어 돕슨
리차드 윌리엄스
이안 구렐
사다나 포디체티
데이비드 페어맨
피터 손턴
필립 뉴턴
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20190129925A publication Critical patent/KR20190129925A/ko
Application granted granted Critical
Publication of KR102711884B1 publication Critical patent/KR102711884B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020197030092A 2017-03-16 2018-03-16 항-par2 항체 및 그의 용도 Active KR102711884B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US62/472,462 2017-03-16
US201862637766P 2018-03-02 2018-03-02
US62/637,766 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
KR20190129925A KR20190129925A (ko) 2019-11-20
KR102711884B1 true KR102711884B1 (ko) 2024-10-02

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030092A Active KR102711884B1 (ko) 2017-03-16 2018-03-16 항-par2 항체 및 그의 용도

Country Status (30)

Country Link
US (4) US10836822B2 (cg-RX-API-DMAC7.html)
EP (2) EP4681726A3 (cg-RX-API-DMAC7.html)
JP (3) JP7222901B2 (cg-RX-API-DMAC7.html)
KR (1) KR102711884B1 (cg-RX-API-DMAC7.html)
CN (1) CN110446720B (cg-RX-API-DMAC7.html)
AU (3) AU2018235031B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018752A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055251A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002626A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019010975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190417A (cg-RX-API-DMAC7.html)
DK (1) DK3596125T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056721T3 (cg-RX-API-DMAC7.html)
FI (1) FI3596125T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251643T1 (cg-RX-API-DMAC7.html)
IL (1) IL269134B2 (cg-RX-API-DMAC7.html)
LT (1) LT3596125T (cg-RX-API-DMAC7.html)
MA (1) MA49886A (cg-RX-API-DMAC7.html)
MX (1) MX2019010802A (cg-RX-API-DMAC7.html)
NZ (1) NZ757915A (cg-RX-API-DMAC7.html)
PH (1) PH12019502087A1 (cg-RX-API-DMAC7.html)
PL (1) PL3596125T3 (cg-RX-API-DMAC7.html)
PT (1) PT3596125T (cg-RX-API-DMAC7.html)
RS (1) RS67581B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908056QA (cg-RX-API-DMAC7.html)
SI (1) SI3596125T1 (cg-RX-API-DMAC7.html)
TW (1) TWI788332B (cg-RX-API-DMAC7.html)
UA (1) UA125757C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018167322A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906004B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
AU2024212070A1 (en) 2023-01-25 2025-07-31 Medimmune Limited Migraine therapy
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20070053911A1 (en) * 2003-03-11 2007-03-08 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2010017086A1 (en) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
HUE051130T2 (hu) * 2008-08-07 2021-03-01 Idexx Lab Inc Eljárások szimmetrikus dimetilarginin kimutatására
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP3160996B1 (en) 2014-06-30 2022-06-08 Merck Patent GmbH Anti-tnfa antibodies with ph-dependent antigen binding
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Also Published As

Publication number Publication date
CL2019002626A1 (es) 2019-12-06
US20210061905A1 (en) 2021-03-04
US20260078180A1 (en) 2026-03-19
BR112019018752A2 (pt) 2020-05-05
JP2025102812A (ja) 2025-07-08
UA125757C2 (uk) 2022-06-01
ES3056721T3 (en) 2026-02-24
JP2020509762A (ja) 2020-04-02
CR20190417A (es) 2019-12-06
HRP20251643T1 (hr) 2026-02-13
SI3596125T1 (sl) 2026-01-30
IL269134B2 (en) 2024-07-01
ZA201906004B (en) 2025-10-29
CN110446720B (zh) 2023-09-12
TWI788332B (zh) 2023-01-01
JP2023055895A (ja) 2023-04-18
CO2019010975A2 (es) 2019-10-21
CN110446720A (zh) 2019-11-12
KR20190129925A (ko) 2019-11-20
MX2019010802A (es) 2019-10-30
CA3055251A1 (en) 2018-09-20
DK3596125T3 (da) 2025-12-22
WO2018167322A1 (en) 2018-09-20
PH12019502087A1 (en) 2020-03-09
EP4681726A2 (en) 2026-01-21
IL269134B1 (en) 2024-03-01
EP3596125B1 (en) 2025-11-19
AU2025203947A9 (en) 2026-03-19
AU2018235031B2 (en) 2021-08-12
LT3596125T (lt) 2026-01-26
FI3596125T3 (fi) 2025-12-29
EP3596125A1 (en) 2020-01-22
TW201843176A (zh) 2018-12-16
NZ757915A (en) 2023-05-26
PT3596125T (pt) 2025-11-27
JP7222901B2 (ja) 2023-02-15
IL269134A (en) 2019-11-28
AU2025203947A1 (en) 2025-06-19
US10836822B2 (en) 2020-11-17
EP4681726A3 (en) 2026-04-01
PL3596125T3 (pl) 2026-02-09
US11591389B2 (en) 2023-02-28
RS67581B1 (sr) 2026-01-30
AU2021257983A1 (en) 2021-11-25
SG11201908056QA (en) 2019-09-27
AU2021257983B2 (en) 2025-02-27
MA49886A (fr) 2020-06-24
AU2018235031A1 (en) 2019-10-31
US20230242639A1 (en) 2023-08-03
US20180305450A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2021257983B2 (en) Anti-par2 antibodies and uses thereof
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
US11926661B2 (en) Human antibodies to artemin and methods of use thereof
US12110336B2 (en) Method for treating a neurodegenerative disease by administering an anti-cellular prion protein (PrPc) antibody
EA044850B1 (ru) Антитела к par2 и пути их применения
US20250043017A1 (en) BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
BR122025022029A2 (pt) Anticorpos anti-par2 ou seu fragmento de ligação ao antígeno, ácido nucleico, vetor, célula hospedeira, composição e seus usos
TW202519559A (zh) 雙特異性PD-L1xCD28抗體及其使用方法
KR20250156803A (ko) 항-cd3 다중특이적 항체 및 사용 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210308

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230912

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240624

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240925

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240926

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PA0102 Application to register extension of term of patent right following delayed registration